Speakers

Expand/Collapse

Richard Baum

Theranostics Center for Molecular Radiotherapy and Molecular Imaging

Day One

Thursday 13th December 2018

9:00 am | Keynote Presentation: The Power of Precision Oncology: Past, Present and Future of Molecular Imaging and Targeted Radioisotope Therapy of Cancer

Urs Hagemann
Laboratory Head
Bayer

  • Ained biologist (University of Freiburg, Germany) with PhD rer. nat. in protein engineering
  • Ten years of experience in the pharmaceutical industry from early drug discovery to clinical development in oncology
  • Since 2012, focusing on the development of targeted alpha emitting radiopharmaceuticals
  • Proven track record in antibody-based therapeutics including radiopharmaceuticials

Day One

Thursday 13th December 2018

3:00 pm | Panel Discussion: Are Targeted Alpha Emitting Therapies the Endgame of Radiopharmaceutical Progress?

2:00 pm | Targeted Thorium-227 Conjugates - Exploring the potential of Bayer’s’ novel targeted alpha therapy platform in solid tumors

Cristina Müller
Research Group Leader at Paul Scherrer Institute and Private Docent
ETH Zurich

Cristina Müller is a Research Group Leader at the Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute and Private Docent at ETH Zurich in Switzerland. She studied Pharmaceutical Sciences and obtained her PhD at ETH Zurich in 2005. As a postdoc fellow, she worked at the Erasmus Medical Center in Rotterdam. After returning to Switzerland, she won a fellowship from the Swiss National Science Foundation and built up her own research group at CRS. She focused on the development of folate-receptor targeted radionuclide therapy, which was also the topic of her Habilitation thesis to obtain a PD title at ETH in 2014. Currently, she supervises a well-established research group at PSI and conducts research dedicated to the design and evaluation of small-molecular-weight ligands for radiotheragnostic applications. Among the main interests are the investigation and application of exotic radionuclides for radiotheragnostic applications.

Day One

Thursday 13th December 2018

11:30 am | Exotic Radionuclides for Radiotheragnostic Applications

Matt Harris
Chief Executive Officer
Clarity Pharmaceuticals

Matt is the founding CEO of Clarity with 20 years experience in cancer research, nuclear medicine and business. After starting his career in radiopharmaceutical manufacture in the early 90s, he completed a PhD in cancer research from the Australian National University before an academic position in the USA. In 2007, Matt co-founded TM Ventures, a commercialisation company which aimed to create start-ups while also providing investment and business development services to Australian universities and companies in life sciences. His knowledge of nuclear medicine helped him identify the potential of Clarity’s technology while his corporate expertise enabled the business to flourish. Dr Harris has an MBA from the Australian Graduate School of Management.

Day One

Thursday 13th December 2018

3:00 pm | Panel Discussion: Are Targeted Alpha Emitting Therapies the Endgame of Radiopharmaceutical Progress?

12:00 pm | Copper-64/67 Targeted radiopharmaceuticals, Next Generation Theranostics

Greg Mullen
Chief Executive Officer
Theragnostics

Day Two

Thursday 13th December 2018

12:00 pm | Novel Targets in Radiopharmaceuticals

Chris Leamon
Vice President of Research
Endocyte

.S.           Baldwin Wallace University (Berea, Ohio) Ph.D.     Purdue University Dr. Leamon is Vice President of Research at Endocyte, Inc., a Novartis company. He received an ACS-certified B.S. degree in Chemistry from Baldwin Wallace University (1988) and a Ph.D. in Chemistry from Purdue University (1993).  Dr. Leamon has spent over 30 years working in the drug delivery field, and is credited for conducting the groundbreaking experiments in folate-targeted technology as well as for exemplifying this novel therapeutic approach for treating cancer.  Dr. Leamon has published 90 articles and is an inventor on more than 45 issued or submitted patents involving drug targeting, including those which cover vintafolide and etarfolatide. In 2015 he was the recipient of the 2015 American Chemical Society, George and Christine Sosnovsky Award for Cancer Research.  Prior to joining Endocyte in February 1999, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome and DNA drug delivery for GlaxoSmithKline, Inc. and Ionis Pharmaceuticals, Inc.  As the head of Endocyte’s Discovery team for the past 20 years, Dr. Leamon remains active in the research and development of targeted radioimaging, radio-, (RLT), chemo- (SMDC) and immuno-therapeutic medicines, including CAR T approaches, for the treatment of cancer and inflammatory diseases. To date, his efforts have yielded 8 clinically investigated agents.

Day Two

Thursday 13th December 2018

9:00 am | Ligand Targeted Cancer Therapy: Shifting from chemo to radiotherapy

Dale Ludwig
Chief Scientific Officer
Actinium Pharmaceuticals

Day Two

Thursday 13th December 2018

10:00 am | Leveraging the Power of Radioimmunotherapy in Cancer Treatment: Radio-Conjugate Therapeutic Combinations and Targeted Conditioning Regimens for Cell Therapy

Jostein Dahle
Chief Scientific Officer
Nordic Nanovector

Dr. Dahle has more than 20 years of experience in cancer research. He is one of the inventors of Betalutin® and founders of Nordic Nanovector. Dr. Dahle has previously held the position of CEO of Nordic Nanovector and leader of the radioimmunotherapy group at Institute for Cancer Research at the Norwegian Radium Hospital. He has published more than 50 papers in the field of cancer and biotechnology. Dr. Dahle holds an MSc in biophysics from the Norwegian University for Science and Technology in Trondheim (1995), a PhD in radiation biology from University of Oslo (2000) and he received post-doctoral training in UV-carcinogenesis in the department of radiation biology at the Norwegian Radium Hospital (2001-2004).

Day Two

Thursday 13th December 2018

9:30 am | Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic Leukaemia (CLL) and non-Hodgkin lymphoma (NHL)

Tony Lahoutte
Chief Scientific Officer
Camel-IDS

Tony Lahoutte, MD ,Phd is head of the department of nuclear medicine at UZ Brussel and head of the molecular imaging research unit at the Vrije Universiteit Brussel (VUB) in Belgium. In 2014 he co-founded the company Camel-IDS NV that is developing a pipeline of radio-immuno therapeutics where he is CSO. He obtained his medical degree in 1998 and started his research activities in combination with a residency program in nuclear medicine. His current research is focused on the development and clinical translation of molecular imaging probes and targeted radionuclide therapies for the detection and treatment of cancer.

Day Two

Thursday 13th December 2018

3:00 pm | Single Domain Antibodies in Nuclear Medicine

Christiane Smerling
Head of Nuclear Medicine & Imaging
3B Pharmaceuticals

Christiane Smerling has been Head of Nuclear Medicine & Imaging at 3B Pharmaceuticals since it started operations in 2009. She has established 3BP's radiopharmaceutical business and is responsible for 3BP's theragnostic development programs. Her focus is the development of targeted radiopharmaceuticals and matching diagnostic imaging agents for oncology indications with high unmet medical need. She also manages the business development and partnering activities of 3BP's Nuclear Medicine Division. Prior to joining 3B Pharmaceuticals, Christiane worked as a scientist at Jerini AG. Christiane received her PhD from the University of Cambridge and her degree in biochemistry from the Freie Universität Berlin.

Day One

Thursday 13th December 2018

9:30 am | New solid tumor targets for targeted radiopharmaceutical therapy using peptides and small molecules

Marc Robillard
Chief Executive Officer
Tagworks Pharmaceuticals

Dr. Robillard initiated and led the team working on Tagworks’ In Vivo Chemistry within Philips Research from 2006 until the spinout end of 2011. In 2003, he joined Philips Research to define and initiate their molecular medicine program in conjunction with the building of the corresponding laboratory facilities. As senior scientist and project leader he was involved in several imaging and drug delivery projects before creating the In Vivo Chemistry technology. Prior to Philips he worked at Kreatech Diagnostics on the development of a portfolio of probes for drug targeting and microarray-based detection of DNA, RNA and proteins. In addition he was a visiting scientist at the School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, and he worked at the CRO Syncom as a synthetic chemist. Dr. Robillard obtained his MSc and PhD in bio(in)organic chemistry at, respectively, the University of Groningen and the Leiden Institute of Chemistry, The Netherlands. He has published 34 peer-reviewed papers and is a co-inventor on 18 patents.

Day One

Thursday 13th December 2018

4:30 pm | In-Vivo Click Strategies for Antibody-Based Imaging and Radiotherapy

Melpomeni Fani
Professor of Radiopharmaceutical Chemistry Research and Development
University Hospital of Basel

Melpomeni Fani is Professor of Radiopharmaceutical Chemistry and the head of the division of Radiopharmaceutical Chemistry, Research and Development, at the University Hospital Basel, Switzerland. Her focus is on the development of radiolabelled peptides and other biomolecules, for cancer imaging and therapy. She is active in preclinical research and clinical translation. She has authored 50+ scientific papers and 5 invited book chapters. She is in the editorial board of the Journal of Nuclear Medicine and Frontiers in Medicine, member of EANM, SNMMI and ESMI and expert board member on (radio)peptides in various pharmaceutical companies. Prof. Fani earned her Master degree in Biochemistry (2000) and her PhD in Radiopharmacy (2003) from the University of Athens, Greece.

Day Two

Thursday 13th December 2018

11:30 am | Targeting G-Protein Coupled Receptors with Radiolabelled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside

Marian Meckel
Research & Development Lead
ITG

  • ITG GmbH, Head of Production 2018 -
  • ITG GmbH, Head of R&D 2017-
  • ITG GmbH ,Sales Department 2015-2017
  • University of Mainz, Institute of Nuclear Chemistry 2010-2015

Day Two

Thursday 13th December 2018

1:30 pm | Manufacturing of EndolucinBeta (Lu-177 Chloride)

Amal Saidi
Scientist
OranoMed

Amal Saidi joined Orano Med in 2016 as a Scientist involved in the preclinical development of radiotherapies with alpha emitters. She previously spent three years working as a Team Leader for Roche in the AREVA-Roche Common Laboratory (ARcoLAB) overseeing preclinical studies involving pre-targeted radioimmunotherapies. Dr. Saidi received her Ph.D. in Genetics from Fritz Lipmann Institute-Leibniz Institute for Age Research.

Day One

Thursday 13th December 2018

2:30 pm | Preclinical Development of 212Pb-DOTAMTATE in a Neuroendocrine Tumor Model

Chris Behrenbruch
Chief Executive Officer
Telix Pharmaceuticals

Chris Behrenbruch is the co-founder and CEO of Telix Pharmaceuticals Limited (ASX:TLX). He has 20 years of commercial and product development experience in the field of nuclear medicine, from "start-up" to "grown-up" companies. Prior executive roles in the field of nuclear medicine and radiology have included companies such as Mirada Solutions, CTI Molecular Imaging, Siemens Healthcare and ImaginAb – he has also consulted extensively to the biopharmaceutical industry. Chris received his doctorate in biomedical engineering from the University of Oxford, an MBA jointly from NYU Stern and the London School of Economics and a JD (Law) from the University of Melbourne.

Day Two

Thursday 13th December 2018

2:00 pm | Current Radiopharmaceutical Manufacturing Challenges: From Pilot to Scale-Up

Daniel Stevens
Global Development Lead
IPSEN

Day Two

Thursday 13th December 2018

3:30 pm | Panel Discussion: Clinical Trial Considerations over the Next 12 Months

Diane Chisholm
Head of Clinical Operations
Blue Earth Diagnostics

Day Two

Thursday 13th December 2018

3:30 pm | Panel Discussion: Clinical Trial Considerations over the Next 12 Months

Izabela Tworowksa
Chief Scientific Officer
Radiomedix

Day Two

Thursday 13th December 2018

11:00 am | Topic To Be Confirmed

Twan Lammers
Professor
Aachen University

Twan Lammers obtained a DSc in Radiation Oncology from Heidelberg University in 2008 and a PhD in Pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at RWTH Aachen University Clinic. In 2014, he was promoted to full professor of medicine. He has published over 150 research articles and reviews, and has received several scholarships and award. He is associate editor for Europe for the Journal of Controlled Release. His primary research interests include drug targeting to tumors, image-guided drug delivery and tumor-targeted combination therapies

Day One

Thursday 13th December 2018

5:00 pm | Imaging Biomarkers in Cancer Nanomedicine

Maurizio Mariani
Head of Research
Advanced Accelerator Applications, A Novartis Company

Day One

Thursday 13th December 2018

4:00 pm | Relevance of dosimetry and the Lutathera experience